These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 10071523

  • 1. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.
    Forsyth LM, Preuss HG, MacDowell AL, Chiazze L, Birkmayer GD, Bellanti JA.
    Ann Allergy Asthma Immunol; 1999 Feb; 82(2):185-91. PubMed ID: 10071523
    [Abstract] [Full Text] [Related]

  • 2. Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome.
    Santaella ML, Font I, Disdier OM.
    P R Health Sci J; 2004 Jun; 23(2):89-93. PubMed ID: 15377055
    [Abstract] [Full Text] [Related]

  • 3. [Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome].
    Alegre J, Rosés JM, Javierre C, Ruiz-Baqués A, Segundo MJ, de Sevilla TF.
    Rev Clin Esp; 2010 Jun; 210(6):284-8. PubMed ID: 20447621
    [Abstract] [Full Text] [Related]

  • 4. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
    Amsterdam JD, Shults J, Rutherford N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan 01; 32(1):100-6. PubMed ID: 17804135
    [Abstract] [Full Text] [Related]

  • 5. Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
    Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H.
    Am J Med; 2006 Feb 01; 119(2):167.e23-30. PubMed ID: 16443425
    [Abstract] [Full Text] [Related]

  • 6. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.
    Demarin V, Podobnik SS, Storga-Tomic D, Kay G.
    Drugs Exp Clin Res; 2004 Feb 01; 30(1):27-33. PubMed ID: 15134388
    [Abstract] [Full Text] [Related]

  • 7. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.
    McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G.
    QJM; 2006 Jul 01; 99(7):461-8. PubMed ID: 16809351
    [Abstract] [Full Text] [Related]

  • 8. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 01; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 9. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.
    Birkmayer JG.
    Ann Clin Lab Sci; 1996 Jun 01; 26(1):1-9. PubMed ID: 8834355
    [Abstract] [Full Text] [Related]

  • 10. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
    Cleare AJ, O'Keane V, Miell JP.
    Psychoneuroendocrinology; 2004 Jul 01; 29(6):724-32. PubMed ID: 15110921
    [Abstract] [Full Text] [Related]

  • 11. Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats.
    Birkmayer JG, Nadlinger K.
    Drugs Exp Clin Res; 2002 Jul 01; 28(5):185-92. PubMed ID: 12635493
    [Abstract] [Full Text] [Related]

  • 12. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, controlled, double-blind trial.
    Castro-Marrero J, Sáez-Francàs N, Segundo MJ, Calvo N, Faro M, Aliste L, Fernández de Sevilla T, Alegre J.
    Clin Nutr; 2016 Aug 01; 35(4):826-34. PubMed ID: 26212172
    [Abstract] [Full Text] [Related]

  • 13. The assessment of the energy metabolism in patients with chronic fatigue syndrome by serum fluorescence emission.
    Mikirova N, Casciari J, Hunninghake R.
    Altern Ther Health Med; 2012 Aug 01; 18(1):36-40. PubMed ID: 22516851
    [Abstract] [Full Text] [Related]

  • 14. Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
    Castro-Marrero J, Segundo MJ, Lacasa M, Martinez-Martinez A, Sentañes RS, Alegre-Martin J.
    Nutrients; 2021 Jul 30; 13(8):. PubMed ID: 34444817
    [Abstract] [Full Text] [Related]

  • 15. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial.
    Costabile RA, Spevak M.
    J Urol; 1999 Jun 30; 161(6):1819-22. PubMed ID: 10332444
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 30; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 17. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J.
    Clin Ther; 2006 May 30; 28(5):689-706. PubMed ID: 16861091
    [Abstract] [Full Text] [Related]

  • 18. The effect of granisetron, a 5-HT3 receptor antagonist, in the treatment of chronic fatigue syndrome patients--a pilot study.
    The GK, Prins J, Bleijenberg G, van der Meer JW.
    Neth J Med; 2003 Sep 30; 61(9):285-9. PubMed ID: 14692441
    [Abstract] [Full Text] [Related]

  • 19. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
    Khurshudian AV.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan 30; 95(1):38-44. PubMed ID: 12539025
    [Abstract] [Full Text] [Related]

  • 20. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.
    Clin Ther; 2007 Oct 30; 29(10):2179-93. PubMed ID: 18042474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.